Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Natera, Inc. (NASDAQ: NTRA) reported positive first quarter financial results for 2024, with $367.7 million in total revenues, a 52.1% increase from the previous year. The company achieved a gross margin of 56.7%, processed 735,800 tests, and had a net loss of $67.6 million. Natera expects total revenue of $1.42 billion to $1.45 billion for 2024.
Natera, Inc. announced a new publication in JCO Precision Oncology showcasing the effectiveness of its Signatera test in detecting breast cancer recurrence early. The study involved 156 early-stage breast cancer patients followed for up to 12 years post-surgery. Signatera detected relapse 38 months earlier than imaging, with an 88.2% sensitivity rate. Patients testing positive for ctDNA had worse survival outcomes. The study emphasizes the importance of early recurrence detection and long-term monitoring in breast cancer patients.
Natera, Inc. (NASDAQ: NTRA) will report its first quarter 2024 results on May 9. The company is a global leader in cell-free DNA and genetic testing. The earnings conference call will take place at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Natera, Inc. (NASDAQ: NTRA) has launched a new cfDNA-based fetal RhD test to support Ob/Gyn physicians and patients during a nationwide shortage of RhIg therapy. The test offers 100% sensitivity and >99% specificity, and can be conducted as early as nine weeks gestation. This initiative is important to prevent complications from alloimmunization in pregnancies where the maternal blood type is RhD-negative and the fetal blood type is RhD-positive. The product launch was supported by a large clinical validation study with over 650 patients, demonstrating Natera's commitment to accurate and reliable diagnostics in women's health.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
